Biomarker profiles that differentiate type-1 and type 2 myocardial infarction

Area of Science:

• Cardiology
• Biomarker Discovery
• Acute Cardiac Care

Background:

• Accurate differentiation between type-1 myocardial infarction (T1MI) and type-2 myocardial infarction (T2MI) is essential upon patient admission and during hospitalization.
• Misclassification can lead to unnecessary invasive procedures and inappropriate admissions to acute cardiac care units.
• Establishing a simple diagnostic profile using readily available biomarkers can improve clinical decision-making.

Purpose of the Study:

• To define a simple biomarker profile for differentiating T1MI from T2MI.
• To assess the utility of commonly used biomarkers in distinguishing these myocardial infarction types.
• To identify predictors for T1MI in patients presenting with non-ST-elevation acute myocardial infarction (NSTEMI).

Main Methods:

• Prospective observational study of 213 consecutive patients with provisional NSTEMI diagnosis.
• Final diagnosis of T1MI, T2MI, or non-ischemic acute myocardial injury (NAMI) based on clinical and instrumental findings.
• Assessment of high-sensitivity Troponin I (hs-cTnI), CK-MB, C-reactive protein (CRP), procalcitonin (PCT), and NT-proBNP.

Main Results:

• Hs-cTnI peak/PCT ratio and hs-cTnI peak/NT-proBNP ratio significantly differentiated T1MI from T2MI and T2MI + NAMI.
• Hs-cTnI peak/PCT ratio was identified as a predictor of T1MI (OR 1.03, 95% CI 1.01-1.06, p < 0.05) with 0.704 accuracy.
• No significant differences were detected between T2MI and NAMI groups.

Conclusions:

• The admission biomarker profile, particularly hs-cTnI ratios with PCT and NT-proBNP, can differentiate T1MI from T2MI in NSTEMI patients.
• This biomarker profile aids in avoiding unnecessary invasive exams and optimizing acute cardiac care unit admissions.